Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brad Rosbrook

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2022
Reply to R. Sun et alAndrew J Armstrong, Brad Rosbrook, Shunsuke Yamada, et al.
Targeted Oncology|January 7, 2021
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with SunitinibNicola Fazio, Matthew Kulke, Brad Rosbrook, et al.
Future Oncology (London, England)|February 1, 2019
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety dataJuan W Valle, Ivan Borbath, Brad Rosbrook, et al.
Future Oncology (London, England)|July 31, 2018
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III dataXinan Sheng, Feng Bi, Xiubao Ren, et al.
Clinical Genitourinary Cancer|May 5, 2021
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell CarcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baselineLaurent Claret, Jenny Zheng, Francois Mercier, et al.
Future Oncology (London, England)|August 1, 2023
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Clinical Genitourinary Cancer|June 2, 2018
Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk GroupBrian I Rini, Thomas E Hutson, Robert A Figlin, et al.
Clinical Genitourinary Cancer|September 1, 2015
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell CarcinomaBrian I Rini, Bernard Escudier, Subramanian Hariharan, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2022
Reply to R. Sun et alAndrew J Armstrong, Brad Rosbrook, Shunsuke Yamada, et al.
Targeted Oncology|January 7, 2021
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with SunitinibNicola Fazio, Matthew Kulke, Brad Rosbrook, et al.
Future Oncology (London, England)|February 1, 2019
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety dataJuan W Valle, Ivan Borbath, Brad Rosbrook, et al.
Future Oncology (London, England)|July 31, 2018
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III dataXinan Sheng, Feng Bi, Xiubao Ren, et al.
Clinical Genitourinary Cancer|May 5, 2021
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell CarcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baselineLaurent Claret, Jenny Zheng, Francois Mercier, et al.
Future Oncology (London, England)|August 1, 2023
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Clinical Genitourinary Cancer|June 2, 2018
Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk GroupBrian I Rini, Thomas E Hutson, Robert A Figlin, et al.
Clinical Genitourinary Cancer|September 1, 2015
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell CarcinomaBrian I Rini, Bernard Escudier, Subramanian Hariharan, et al.
Pageof 5